Please assess the completion status of the following clinical trial:

Trial Title: Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Lean cohort~1. Men and women\>18 years of age;~2. Normal body weight (18.5 ≤ BMI ≤25 kg/m2);~3. T2D patients can be on treatment with oral glucose lowering therapies, and if they are, they must have been on these treatments for at least 12 weeks prior to screening;~4. 6.5≤HBA1c≤10% at screening;~5. Agreement to maintain prior diet and exercise habits for the duration of the study.~Overweight cohort~1. Men and women\>18 years of age;~2. Increased body weight (BMI \>27 kg/m2);~3. T2D patients can be on treatment with oral glucose lowering therapies, and must have been on these treatments for at least 12 weeks prior to screening;~4. 6.5≤HBA1c≤10% at screening;~5. Agreement to maintain prior diet and exercise habits for the duration of the study.~Exclusion Criteria:~1. Any type of diabetes other than T2D;~2. Past history of significant CAD;~3. Known HF;~4. Significant renal impairment (eGFR\<30ml/min/m2);~5. Participation in a clinical trial of an investigational medicinal product (CTIMP) in the preceding 12 weeks;~6. Known hypersensitivity to dobutamine or gadolinium or any other contra-indications to MRI;~7. Participants with obesity where their girth exceeds the scanner bore;~8. History of pancreatitis;~9. Any history of liver disease;~10. Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2);~11. Prior or current use of thiazolidinediones (aka PPAR-γ agonists), fibrates, GLP-1RA or insulin;~12. Patients that are pregnant (female participants only);~13. Inflammatory bowel disease~14. Diabetic gastroparesis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liraglutide-Pioglitazone (Type: ACTIVE_COMPARATOR): Participants randomised to receive liraglutide treatment for 16 weeks, followed by an 8 week washout then commencing 16 weeks of treatment with pioglitazone.
- Pioglitazone-Liraglutide (Type: ACTIVE_COMPARATOR): Participants randomised to receive pioglitazone treatment for 16 weeks, followed by an 8 week washout then commencing 16 weeks of treatment with liraglutide.

Based on this trial design, predict the completion outcome and termination type (if applicable).